Specify a stock or a cryptocurrency in the search bar to get a summary
Avadel Pharmaceuticals PLC
AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, 2
Analytics
WallStreet Target Price
24.6 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures AVDL
Dividend Analytics AVDL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AVDL
Stock Valuation AVDL
Financials AVDL
Results | 2019 | Dynamics |